New HIV Prevention Shot Shows Zero Infections in Trial

A breakthrough HIV prevention tool has shown near-perfect results in clinical trials, and Nigeria is positioned to benefit once it becomes widely available.

The World Health Organization recommended lenacapavir in July 2025 as a new option for preventing HIV infection. Unlike daily pills that require consistent adherence, this medication works as a simple injection given just twice a year.

The results from clinical trials are remarkable. In the PURPOSE 1 trial, not a single person who received lenacapavir became infected with HIV. The PURPOSE 2 trial saw only two infections among participants, far fewer than comparison groups.

For Nigeria, where 1.9 million people live with HIV and new infections continue especially among young women and key populations, this represents a potential game changer. Young women aged 20 to 24 face more than three times the HIV risk of young men the same age.

The twice-yearly schedule solves real problems that have limited previous prevention efforts. Daily oral PrEP can be difficult to maintain where stigma, privacy concerns, and pill fatigue create barriers. A shot every six months removes those daily hurdles while providing strong protection.

The Bright Side

Here's where the story gets even better: affordability is coming within reach. While lenacapavir costs around $28,000 per person yearly in the United States, a partnership between UNAIDS, the Gates Foundation, and generic manufacturers has outlined a path to roughly $40 per person per year for low and middle-income countries including Nigeria.

That price difference transforms lenacapavir from an impossible dream into a realistic prevention tool. Six generic manufacturers are preparing to produce the medication under voluntary licenses from the original maker, Gilead.

The timeline requires patience but offers genuine hope. Large-scale generic availability is expected starting in 2027, pending regulatory approvals and manufacturing ramp-up. In the meantime, a Global Fund-supported arrangement aims to reach up to two million people globally over three years as a bridge.

Nigeria's health system is already preparing for implementation. The medication will need regulatory approval from NAFDAC, trained healthcare workers for safe injection delivery, and integration into existing HIV prevention services. Community trust and confidential service delivery will be essential to reach people at highest risk without stigma.

The World Health Organization positions lenacapavir as an additional choice alongside existing prevention methods, not a replacement. Choice matters deeply for populations that haven't been well served by daily pills or other current options.

This isn't just about one medication working in a laboratory setting. It's about real people gaining access to protection that fits their lives, delivered through systems that respect their privacy and meet them where they are.

Nigeria's progress on HIV treatment has been real, but prevention gaps have persisted, and this breakthrough offers a practical new tool to close them.